Saxenda weight loss results: what the clinical data actually shows

What did @paulamoraiss_ actually say?

Honestly? Not much that can be evaluated. The transcript captured from this video is essentially garbled and incoherent, a repeated loop of fragmented phrases with no discernible health claims attached to it. The caption reads "Evolução usando saxenda" which translates from Portuguese as "Evolution using Saxenda," suggesting this is a before-and-after or progress video documenting personal weight loss results on liraglutide (the active drug in Saxenda). But the spoken content offers nothing to fact-check in any meaningful clinical sense.

This appears to be a visual progress video where the creator is showing physical transformation rather than making specific medical or pharmacological claims. That context matters. A lot of GLP-1 content on TikTok operates this way: the "claim" is the body, not the words. And that comes with its own set of problems worth talking through.

Does the science back this up?

Saxenda (liraglutide 3.0 mg) is a legitimate, FDA-approved GLP-1 receptor agonist for chronic weight management. The clinical data supporting it is real and reasonably strong. Weight loss results vary considerably between individuals, so any single person's "evolution" may or may not be typical.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) followed 3,731 patients and found that liraglutide 3.0 mg produced an average weight loss of about 8 percent of body weight over 56 weeks, compared to roughly 2.6 percent with placebo. That is meaningful but not dramatic. Roughly a third of participants lost 10 percent or more of their body weight, while another significant chunk lost less than 5 percent. If you are watching a TikTok progress video and comparing your results to what you see on screen, that is a statistically risky exercise. Individual responses to liraglutide range widely based on baseline metabolic health, adherence, diet, and genetics.

What did they get wrong (or right)?

Because the transcript yields no coherent spoken claims, there is nothing to directly correct. But the format itself, a before-and-after progress video promoting a prescription GLP-1 drug, carries implicit messaging that deserves scrutiny. Showing personal results without context can function as anecdotal promotion even when no explicit claim is made.

What the creator arguably got right: Saxenda is a real drug with documented weight loss effects. Sharing a personal experience is not inherently irresponsible. People document their health journeys, and that is not automatically misleading.

What is missing and matters: no mention of side effects, no acknowledgment that results are not universal, no discussion of the need for medical supervision, and no clarity on whether this reflects typical outcomes. The SCALE trial data makes clear that a meaningful portion of patients on liraglutide do not achieve dramatic results. A progress reel implies outcomes that may not generalize. That gap between individual showcase and population-level data is where misinformation quietly lives in health content.

What should you actually know?

If you are considering Saxenda after watching a progress video, here is what the research actually says. Liraglutide 3.0 mg is approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It works by mimicking GLP-1, slowing gastric emptying and reducing appetite through central nervous system pathways.

Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. The SCALE trial reported that about 40 percent of liraglutide patients experienced nausea, with most cases being mild to moderate. Rare but serious risks include pancreatitis and, based on rodent data, a potential signal for thyroid C-cell tumors. Saxenda carries a black box warning for thyroid cancer risk and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.

Saxenda is also not the same as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). These are different drugs with different mechanisms and different efficacy profiles. Compounded liraglutide is not equivalent to brand-name Saxenda. Any GLP-1 therapy requires a licensed prescriber and ongoing medical monitoring.

• Liraglutide 3.0 mg produces roughly 5 to 8 percent average body weight loss in clinical trials
• Results vary significantly between individuals
• Side effects are common, especially GI symptoms during titration
• A black box warning exists for thyroid tumor risk based on animal studies
• Medical supervision is required throughout treatment